BC
PTCT icon

Boxer Capital’s PTC Therapeutics PTCT Stock Holding History

Boxer Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,000,000
Closed -$33.8M – 56
2019
Q3 		$33.8M Hold
1,000,000
– – 2.45% 16
2019
Q2 		$45M Hold
1,000,000
– – 3.87% 8
2019
Q1 		$37.6M Sell
1,000,000
-1,155,000
-54% -$38.8M 4.35% 10
2018
Q4 		$74M Hold
2,155,000
– – 9.14% 3
2018
Q3 		$101M Buy
2,155,000
+255,000
+13% +$10.6M 11.24% 3
2018
Q2 		$64.1M Sell
1,900,000
-700,000
-27% -$21.8M 7.26% 4
2018
Q1 		$70.2M Buy
2,600,000
+850,000
+49% +$21.5M 7.49% 3
2017
Q4 		$29.2M Buy
1,750,000
+500,000
+40% +$8.46M 5.34% 6
2017
Q3 		$25M Sell
1,250,000
-450,000
-26% -$8.81M 5.69% 7
2017
Q2 		$31.2M Buy
1,700,000
+200,000
+13% +$2.69M 7.41% 6
2017
Q1 		$14.8M Buy
+1,500,000
New +$18.2M 3.23% 8

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Boxer Capital's PTCT Position: Q4 2019 in Review

Boxer Capital sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 1,000,000 shares — an estimated $33.8M sold.

Boxer Capital first reported a position in PTCT in Q1 2017 and held it in 11 quarters. The position peaked at $101M in Q3 2018. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Boxer Capital reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Boxer Capital sold 1,000,000 PTC Therapeutics shares in Q4 2019, an estimated $33.8M.
  • Boxer Capital first reported a position in PTC Therapeutics in Q1 2017 and held it in 11 quarters.
  • Boxer Capital's PTC Therapeutics position peaked at $101M in Q3 2018.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Boxer Capital's 13F filing for Q4 2019, filed 14 Feb 2020.